ANAB
Price
$20.55
Change
+$1.49 (+7.82%)
Updated
Apr 17 closing price
Capitalization
630.2M
19 days until earnings call
QTTB
Price
$2.12
Change
+$0.27 (+14.59%)
Updated
Apr 17 closing price
Capitalization
25.86M
Ad is loading...

ANAB vs QTTB

Header iconANAB vs QTTB Comparison
Open Charts ANAB vs QTTBBanner chart's image
AnaptysBio
Price$20.55
Change+$1.49 (+7.82%)
Volume$599.66K
Capitalization630.2M
Q32 Bio
Price$2.12
Change+$0.27 (+14.59%)
Volume$108.27K
Capitalization25.86M
ANAB vs QTTB Comparison Chart
Loading...
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QTTB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANAB vs. QTTB commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Hold and QTTB is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (ANAB: $20.55 vs. QTTB: $2.12)
Brand notoriety: ANAB and QTTB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANAB: 51% vs. QTTB: 51%
Market capitalization -- ANAB: $630.2M vs. QTTB: $25.86M
ANAB [@Biotechnology] is valued at $630.2M. QTTB’s [@Biotechnology] market capitalization is $25.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANAB’s FA Score shows that 0 FA rating(s) are green whileQTTB’s FA Score has 0 green FA rating(s).

  • ANAB’s FA Score: 0 green, 5 red.
  • QTTB’s FA Score: 0 green, 5 red.
According to our system of comparison, ANAB is a better buy in the long-term than QTTB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANAB’s TA Score shows that 5 TA indicator(s) are bullish while QTTB’s TA Score has 4 bullish TA indicator(s).

  • ANAB’s TA Score: 5 bullish, 3 bearish.
  • QTTB’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ANAB is a better buy in the short-term than QTTB.

Price Growth

ANAB (@Biotechnology) experienced а +26.54% price change this week, while QTTB (@Biotechnology) price change was +26.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

ANAB is expected to report earnings on Aug 11, 2025.

QTTB is expected to report earnings on May 13, 2024.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANAB($630M) has a higher market cap than QTTB($25.9M). ANAB YTD gains are higher at: 55.211 vs. QTTB (-38.372). QTTB has higher annual earnings (EBITDA): -44.5M vs. ANAB (-92.74M). ANAB has more cash in the bank: 385M vs. QTTB (78M). ANAB has less debt than QTTB: ANAB (16M) vs QTTB (18.9M). ANAB has higher revenues than QTTB: ANAB (91.3M) vs QTTB (0).
ANABQTTBANAB / QTTB
Capitalization630M25.9M2,432%
EBITDA-92.74M-44.5M208%
Gain YTD55.211-38.372-144%
P/E RatioN/AN/A-
Revenue91.3M0-
Total Cash385M78M494%
Total Debt16M18.9M85%
FUNDAMENTALS RATINGS
ANAB vs QTTB: Fundamental Ratings
ANAB
QTTB
OUTLOOK RATING
1..100
3215
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
74100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4295
P/E GROWTH RATING
1..100
67100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QTTB's Valuation (56) in the null industry is in the same range as ANAB (84) in the Biotechnology industry. This means that QTTB’s stock grew similarly to ANAB’s over the last 12 months.

ANAB's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as QTTB (100) in the null industry. This means that ANAB’s stock grew similarly to QTTB’s over the last 12 months.

ANAB's SMR Rating (98) in the Biotechnology industry is in the same range as QTTB (100) in the null industry. This means that ANAB’s stock grew similarly to QTTB’s over the last 12 months.

ANAB's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for QTTB (95) in the null industry. This means that ANAB’s stock grew somewhat faster than QTTB’s over the last 12 months.

ANAB's P/E Growth Rating (67) in the Biotechnology industry is somewhat better than the same rating for QTTB (100) in the null industry. This means that ANAB’s stock grew somewhat faster than QTTB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANABQTTB
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 16 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
82%
Bearish Trend 12 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QTTB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMKBX20.340.24
+1.19%
Morgan Stanley Inst Emerging Mkts A
CSVRX36.470.35
+0.97%
Columbia Small Cap Value I R
FISGX34.250.32
+0.94%
Nuveen Small/Mid Cap Growth Opp I
SWSSX30.240.27
+0.90%
Schwab Small Cap Index
GGUPX8.52N/A
N/A
Goldman Sachs Global Rl Estt Secs P

ANAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with CLRB. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANAB
1D Price
Change %
ANAB100%
+7.82%
CLRB - ANAB
45%
Loosely correlated
+5.58%
ADCT - ANAB
41%
Loosely correlated
+4.31%
QTTB - ANAB
41%
Loosely correlated
+14.59%
HRMY - ANAB
39%
Loosely correlated
+1.86%
AMRN - ANAB
38%
Loosely correlated
-2.67%
More

QTTB and

Correlation & Price change

A.I.dvisor indicates that over the last year, QTTB has been closely correlated with CLRB. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if QTTB jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QTTB
1D Price
Change %
QTTB100%
+14.59%
CLRB - QTTB
77%
Closely correlated
+5.58%
ADCT - QTTB
51%
Loosely correlated
+4.31%
MESO - QTTB
51%
Loosely correlated
+3.98%
STOK - QTTB
49%
Loosely correlated
+1.72%
ANAB - QTTB
41%
Loosely correlated
+7.82%
More